This Newsweek story reports on the results of a small study published in the Journal of the American Medical Association. The study compared two methods of delivering a fecal microbiota transplant (FMT), via a colonoscopy or with an oral pill, to treat Clostridium difficile infection. An FMT involves taking feces from a healthy person and transplanting it into a sick person, to see if that can help eradicate unwanted microbes.
Both approaches were equally successful and the oral pill — as might be expected — was perceived as less objectionable by patients. The story covers most of the bases we require, though it was unclear on the availability of the pill-based treatment, and what role standard antibiotics play in treatment and research outcomes.
As the story points out, Clostridium difficile infections in hospital patients is a serious public health problem, infecting “half a million people in the United States per year and killing 15,000 people” annually. Fecal microbiota transplant (FMT) is fast becoming the treatment of choice in these cases and any improvement to facilitate this approach would obviously be welcome. The pill approach diminishes the “yuck factor” with this treatment, based on the study results.
The story does a good job of pointing out one advantage of the pill approach compared to delivery via colonoscopy–the reduced cost. “There was a significant difference in cost. Though the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.”
This was a close call. Early on, it says the pill was 90% effective for treating recurrent Clostridium difficile infections. Later on, the story explains that both were equally successful in treating the Clostridium difficile infections. It would take a bit of deduction to figure out that the 90% treatment rate applies to both the pills and colonoscopies. And the study puts this figure close to 96%.
But we’ll give the benefit of the doubt and rate it satisfactory.
The story gets a satisfactory here for including the differences between the two methods of delivery: One source is quoted saying, “colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person’s body and can be complicated for the people most at risk for C. difficile infections.” It could have gone a step further and reminded readers that a colonoscopy is an invasive procedure with the inherent risks of infection and perforation that obviously aren’t there when taking a pill. The story did not mention the other adverse events described in the paper such as nausea and vomiting, though.
The story comments on the size of the study and quotes a researcher about strengths (a randomized, controlled trial) and limitations (selection bias) of the study. Selection bias, in this case, means many people were excluded from the clinical trial if they had any number of issues (patients with severe or complicated cases were excluded, for example), potentially biasing the results. In a more real-world setting, the effectiveness rate may drop once it’s tried on a wider range of people.
The story does include comments from an independent source unaffiliated with the research. But, it doesn’t specify that the source has received research money from a drug company that’s developing microbiome drugs.
Standard treatment for C. diff is antibiotics. This should have been mentioned.
Unfortunately, the story doesn’t spell out whether the pill form FMT is now, or soon will be, available to the public. The story does mention that numerous other clinical trials are using FMT as a possible treatment for various diseases but it is unclear whether the pill form is an option for physicians at this point.
What’s new here is that a pill form for delivery of a fecal transplant is being tested against a colonoscopy. The story established this.
It does not appear to rely on a news release.
Animal studies can reveal important scientific insights and, when appropriately reported, can provide useful news…
This story does a good job putting a new study on chondroitin for knee pain in…
This story discusses the state of evidence for neurofeedback for treating depression, ADD, anxiety, and…
Systematic, Criteria-Driven
We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.
Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.
-Gary Schwitzer, Publisher, HealthNewsReview.org
By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)
Animal studies can reveal important scientific insights and, when appropriately reported, can provide useful news…
This story does a good job putting a new study on chondroitin for knee pain in…
This story discusses the state of evidence for neurofeedback for treating depression, ADD, anxiety, and…
Weekly Digest-- Pharma banks on cancer patients who are ‘determined to keep fighting’ - https://t.co/916BSBxuuW
Not the same. One is run by a professional medical/advocacy group. Other is administered by a university-based journalism training organization. Read the journalist quotes in our piece about how this is different.
@HealthNewsRevu Isn't the Gerontological Society practice of funding fellows for coverage the same as what's used by many journalistic fellowships? See Center for Health Reporting at USC.
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
Animal studies can reveal important scientific insights and, when appropriately reported, can provide useful news…
This story does a good job putting a new study on chondroitin for knee pain in…
This story discusses the state of evidence for neurofeedback for treating depression, ADD, anxiety, and…